GlaxoSmithKline's (NYSE: GSK) problems in China just won't go away. After being accused of an incredible $428 million bribery campaign to entice sales Glaxo's products the Chinese government accused several employees directly.
There are also claims of wrongdoing in several other countries, bringing GSK's international business into an unfortunate spotlight. And now a formal criminal investigation has begun from Britain's Serious Fraud Office in the big pharma's marketing practices.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass discuss what these allegations mean for the big picture for GlaxoSmithKline and its investors.
